Wealth Management Solutions LLC Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Wealth Management Solutions LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,703 shares of the company’s stock after purchasing an additional 300 shares during the period. Johnson & Johnson accounts for 1.1% of Wealth Management Solutions LLC’s holdings, making the stock its 16th biggest position. Wealth Management Solutions LLC’s holdings in Johnson & Johnson were worth $2,067,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. DORCHESTER WEALTH MANAGEMENT Co lifted its stake in shares of Johnson & Johnson by 8.6% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after buying an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P lifted its stake in shares of Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after buying an additional 82,429 shares in the last quarter. AMI Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after buying an additional 1,475 shares in the last quarter. Equitable Holdings Inc. lifted its stake in shares of Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after buying an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd lifted its stake in shares of Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after buying an additional 20,528 shares in the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Credit Suisse Group raised their price objective on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Guggenheim assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective for the company. Piper Sandler cut their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 19th. Finally, Raymond James cut their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $158.91 on Friday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The company’s fifty day moving average is $159.70 and its two-hundred day moving average is $166.23. The stock has a market capitalization of $412.96 billion, a P/E ratio of 33.24, a P/E/G ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. During the same period in the previous year, the firm earned $2.67 EPS. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.00%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is 94.56%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.20% of the stock is owned by insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.